Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Tripolt, NJ; Leber, B; Triebl, A; Köfeler, H; Stadlbauer, V; Sourij, H.
Effect of Lactobacillus casei Shirota supplementation on trimethylamine-N-oxide levels in patients with metabolic syndrome: An open-label, randomized study.
Atherosclerosis. 2015; 242(1):141-144 Doi: 10.1016/j.atherosclerosis.2015.05.005
Web of Science PubMed FullText FullText_MUG


Führende Autor*innen der Med Uni Graz
Stadlbauer-Köllner Vanessa
Tripolt Norbert
Co-Autor*innen der Med Uni Graz
Köfeler Harald
Leber Bettina
Sourij Harald
Triebl Alexander

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Recent studies in animal models have shown a link between ingestion of dietary phosphatidylcholine (PC), choline, l-carnitine and cardiovascular risk. Intestinal microbiota-dependent metabolism of PC and l-carnitine is involved in formation of trimethylamine (TMA), which is further metabolized to the proatherogenic compound trimethylamine-N-oxide (TMAO). It has been suggested that changes in gut microbiota by supplementation of probiotic drinks might alter TMAO levels. Hence, the aim of this analysis was to investigate the impact of Lactobacillus casei Shirota (LcS) on formation of TMAO in subjects with metabolic syndrome. In a single-center, prospective, randomized-controlled study 30 subjects with metabolic syndrome were randomized to receive either 3 times daily 6.5 × 10(9) CFU (colony-forming units) LcS (probiotic group) or not (standard therapy group) for 12 weeks. TMAO plasma levels were quantified by means of liquid chromatography and tandem mass spectrometry. Thirteen patients in the probiotic group and 15 in the standard therapy group finished the study. Mean age was 52 ± 11 and 55 ± 9 years, respectively. TMAO levels decreased during the intervention period in both groups (from 4.66 ± 2.66 μM to 4.31 ± 2.04 μM in the probiotic group and from 4.64 ± 2.75 μM to 4.40 ± 2.14 μM in the control group). Changes in TMAO between subjects receiving LcS (-0.25 ± 2.39 μM) and controls (-0.34 ± 2.23 μM) were not significantly different (p = 0.510). In conclusion, intake of LcS for 12 weeks did not affect levels of TMAO in patients with metabolic syndrome. Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.
Find related publications in this database (using NLM MeSH Indexing)
Adult -
Austria -
Biomarkers - blood
Chromatography, Liquid -
Female -
Gastrointestinal Microbiome -
Humans -
Intestines - microbiology
Lactobacillus casei - growth & development
Lactobacillus casei - metabolism
Male -
Metabolic Syndrome - blood
Metabolic Syndrome - diagnosis
Metabolic Syndrome - microbiology
Metabolic Syndrome - therapy
Methylamines - blood
Middle Aged -
Probiotics - therapeutic use
Prospective Studies -
Tandem Mass Spectrometry -
Time Factors -
Treatment Outcome -

Find related publications in this database (Keywords)
Trimethylamine-N-oxide (TMAO)
Lactobacillus casei Shirota (LcS)
Gut microbiota
Metabolic syndrome
© Med Uni Graz Impressum